Shares of Halyard Health, Inc. (NYSE:HYH) have earned an average recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $41.67.

Several research firms have issued reports on HYH. BidaskClub cut Halyard Health from a “buy” rating to a “hold” rating in a research report on Saturday, July 8th. TheStreet upgraded Halyard Health from a “c” rating to a “b” rating in a research report on Thursday, June 22nd. Zacks Investment Research upgraded Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Wednesday, July 12th. Stephens upgraded Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price objective on shares of Halyard Health in a research report on Thursday, September 21st.

Halyard Health (HYH) traded up 0.09% during trading on Friday, hitting $46.04. 200,744 shares of the stock traded hands. The firm’s 50-day moving average is $45.06 and its 200-day moving average is $40.23. The stock has a market cap of $2.15 billion, a P/E ratio of 44.27 and a beta of 1.75. Halyard Health has a 12 month low of $31.59 and a 12 month high of $46.63.

Halyard Health (NYSE:HYH) last released its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.14. The firm had revenue of $399.20 million during the quarter, compared to analysts’ expectations of $399.16 million. Halyard Health had a return on equity of 8.29% and a net margin of 3.06%. Halyard Health’s revenue was down .2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.45 earnings per share. On average, analysts forecast that Halyard Health will post $1.96 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/halyard-health-inc-hyh-receives-42-25-consensus-target-price-from-analysts/1613639.html.

Several hedge funds have recently made changes to their positions in HYH. State Board of Administration of Florida Retirement System increased its position in shares of Halyard Health by 11.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 32,077 shares of the medical instruments supplier’s stock valued at $1,222,000 after buying an additional 3,230 shares in the last quarter. American Century Companies Inc. purchased a new position in shares of Halyard Health in the first quarter valued at $1,646,000. Bank of New York Mellon Corp increased its position in shares of Halyard Health by 10.0% in the first quarter. Bank of New York Mellon Corp now owns 881,642 shares of the medical instruments supplier’s stock valued at $33,582,000 after buying an additional 80,294 shares in the last quarter. Comerica Bank increased its position in shares of Halyard Health by 4.3% in the first quarter. Comerica Bank now owns 37,158 shares of the medical instruments supplier’s stock valued at $1,464,000 after buying an additional 1,535 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Halyard Health by 1.2% in the first quarter. Swiss National Bank now owns 76,900 shares of the medical instruments supplier’s stock valued at $2,929,000 after buying an additional 900 shares in the last quarter. Institutional investors and hedge funds own 91.02% of the company’s stock.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.